Saturday 17 October 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 13.8%, free cash flow fell 17.3% and total debt rose 4.31%, each against the same quarter a year earlier.
27.82
1.82
−6.14%
Follow PHVS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 13.14 | 1.77 | 6.02 | 15.37 | 11.51 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 42.86 | 27.50 | 29.80 | 33.00 | 29.80 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 14 | 34 | 65 | 82 | 108 | 129 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (5) | (9) | (30) | (50) | (80) | (108) | (143) | (197) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (5) | (9) | (30) | (50) | (80) | (108) | (143) | (197) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (1.05) | (1.85) | (6.12) | (1.66) | (2.39) | (2.84) | (2.68) | (3.36) | |||||
| Cash flow | — | — | (0.95) | (1.54) | (5.06) | (1.73) | (2.11) | (2.62) | (2.41) | (2.62) | |||||
| Capex | — | — | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (0.95) | (1.54) | (5.07) | (1.74) | (2.11) | (2.63) | (2.42) | (2.62) | |||||
| Book value | — | — | 1.17 | 4.32 | 22.56 | 7.97 | 4.68 | 10.83 | 5.36 | 5.19 | |||||
| Shares, m | — | — | 5 | 5 | 5 | 30 | 34 | 38 | 54 | 59 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (7) | (25) | (53) | (71) | (101) | (130) | (155) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | (5) | (7) | (25) | (53) | (71) | (101) | (131) | (155) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 6 | 21 | 109 | 242 | 157 | 415 | 288 | 305 | ||||
| Total debt | — | — | — | — | — | 0 | 0 | 0 | 1 | 1 | |||||
| Net debt | — | — | (6) | (23) | (113) | (248) | (170) | (423) | (303) | (329) | |||||
| Shareholders’ equity | — | — | 6 | 21 | 109 | 242 | 157 | 416 | 290 | 307 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (163.85) | (61.26) | (42.83) | (27.59) | (37.61) | (35.90) | (38.90) | (60.57) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | (38.45) | (67.88) | (45.57) | (28.73) | (40.24) | (38.11) | (41.18) | (66.63) | |||||
Negative figures in brackets.
Charts ten years each
Pharvaris N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | +278.67% (above 0%: growing) | n/m | −41.39% (below 0%: shrinking) | 100.00% | (44,460.56%) | Compare |
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| NVAX Novavax, Inc. | $2.1B | — (loss-making) | — (loss-making) | −76.30% (below 0%: shrinking) | n/m | +42.95% (above 0%: growing) | 74.87% | (96.84%) | Compare |
| VCEL Vericel Corporation | $2.1B | 83.6× | 76.8× | +22.48% (above 0%: growing) | n/m | +17,503.70% (above 0%: growing) | 72.82% | 0.56% | Compare |
| PHVS Pharvaris N.V. | $2.1B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | |
| VERA Vera Therapeutics, Inc. | $2.1B | — (loss-making) | — | — | n/m | −82.47% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| Median of peers | $2.1B | — | — | +8.98% | — | +13.03% | 49.39% | 0.00% |
Pharvaris N.V. (PHVS) key facts
- Pharvaris N.V. (PHVS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PHVS traded at $27.82, a market capitalization of $2.1 billion.
- Return on equity was −66.6% and debt-to-equity 0.00.